ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 6,672 shares, a decrease of 50.1% from the September 15th total of 13,369 shares. Based on an average daily volume of 44,566 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.2% of the shares of the company are short sold.
Institutional Trading of ALPS Medical Breakthroughs ETF
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Harbor Investment Advisory LLC acquired a new stake in ALPS Medical Breakthroughs ETF during the second quarter valued at $29,000. Virtu Financial LLC increased its holdings in ALPS Medical Breakthroughs ETF by 7.3% in the fourth quarter. Virtu Financial LLC now owns 17,967 shares of the company’s stock valued at $920,000 after buying an additional 1,229 shares in the last quarter. Kestra Advisory Services LLC increased its holdings in ALPS Medical Breakthroughs ETF by 27.6% in the first quarter. Kestra Advisory Services LLC now owns 8,186 shares of the company’s stock valued at $428,000 after buying an additional 1,772 shares in the last quarter. Sterling Investment Advisors Ltd. raised its position in shares of ALPS Medical Breakthroughs ETF by 8.1% in the second quarter. Sterling Investment Advisors Ltd. now owns 23,800 shares of the company’s stock worth $1,539,000 after acquiring an additional 1,775 shares during the period. Finally, Silver Oak Securities Incorporated raised its position in shares of ALPS Medical Breakthroughs ETF by 24.4% in the first quarter. Silver Oak Securities Incorporated now owns 16,589 shares of the company’s stock worth $868,000 after acquiring an additional 3,254 shares during the period.
ALPS Medical Breakthroughs ETF Price Performance
SBIO traded up $1.02 during midday trading on Thursday, hitting $52.22. 35,751 shares of the company were exchanged, compared to its average volume of 38,531. The company’s 50 day simple moving average is $62.87 and its 200 day simple moving average is $59.53. ALPS Medical Breakthroughs ETF has a 1-year low of $41.73 and a 1-year high of $70.85.
ALPS Medical Breakthroughs ETF Company Profile
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.
See Also
- Five stocks we like better than ALPS Medical Breakthroughs ETF
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.
